Spatially encoded biological assays

Patent metadata

Field	Value
Publication number	US-10480022-B2
Application number	US-201916276235-A
Country	US
Kind code	B2
Filing date	Feb 14, 2019
Priority date	Apr 5, 2010
Publication date	Nov 19, 2019
Grant date	Nov 19, 2019

Abstract

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

First claim

The invention claimed is:

1. A method for determining a spatial location of a biological molecule of a tissue sample comprising
(a) providing a plurality of beads, wherein the plurality of beads comprise a plurality of binding agents, wherein a binding agent of the plurality of binding agents (i) comprises a coding identifier having a nucleic acid sequence and (ii) is configured to interact with a biological molecule of a tissue sample, wherein the coding identifier corresponds to a location at which the binding agent interacts with a biological molecule of a tissue sample;
(b) contacting the plurality of beads with the tissue sample such that the binding agent interacts with the biological molecule; and
(c) using the coding identifier to identify the location where the binding agent interacted with the biological molecule, thereby determining a spatial location of the biological molecule of the tissue sample.

2. The method of claim 1 , wherein the plurality of beads is provided on a substrate surface.

3. The method of claim 2 , wherein the plurality of beads is provided in wells on the substrate surface.

4. The method of claim 1 , wherein the biological molecule is a nucleic acid.

5. The method of claim 4 , wherein the binding agent of the plurality of binding agents comprises a nucleic acid.

6. The method of claim 5 , wherein the binding agent interacts with the biological molecule via hybridization.

7. The method of claim 1 , wherein the binding agent and coding identifier are provided as a single molecule.

8. The method of claim 7 , wherein the binding agent and coding identifier are provided as a single molecule through nucleic acid synthesis.

9. The method of claim 7 , wherein the binding agent and coding identifier are provided as a ligation product.

10. The method of claim 7 , wherein the binding agent and coding identifier are provided as a single molecule through chemical coupling.

11. The method of claim 1 , wherein the plurality of binding agents comprises an additional binding agent, which (i) comprises an additional coding identifier and (ii) is configured to interact with another biological molecule of the tissue sample, wherein the additional coding identifier is different from the coding identifier of step (a)(i).

12. The method of claim 11 , wherein the additional coding identifier corresponds to a location at which the additional binding agent of the plurality of binding agents interacts with said another biological molecule of the tissue sample.

13. The method of claim 12 , wherein the location at which the binding agent interacts with the biological molecule and the additional binding agent interacts with said another biological molecule is different.

14. The method of claim 13 , wherein the spatial location of the biological molecule and said another biological molecule of the tissue sample is different.

15. The method of claim 1 , wherein step (c) comprises determining the spatial locations of a plurality of biological molecules of the tissue sample simultaneously.

16. The method of claim 1 , wherein step (c) comprises determining presence or absence of the biological molecule at the location at which it is identified.

17. The method of claim 1 , wherein step (c) comprises determining the relative amount of the biological molecule at the location at which it is identified.

18. The method of claim 1 , wherein step (c) comprises determining all or a portion of the nucleic acid sequence of the coding identifier.

19. The method of claim 1 , wherein step (c) comprises sequencing all or a portion of the nucleic acid sequence of the coding identifier.

20. The method of claim 1 , wherein prior to step (c), spatial organization of cells in the tissue sample is preserved.

21. The method of claim 1 , wherein the biological molecule of the biological sample is selected from a protein, a nucleic acid, a lipid, a carbohydrate, and an ion.

22. The method of claim 21 , wherein the biological molecule is part of a multicomponent complex.

23. The method of claim 1 , wherein the tissue sample is a fresh tissue sample.

24. The method of claim 1 , wherein the tissue sample is a preserved tissue sample.

25. The method of claim 24 , wherein the preserved tissue sample is a frozen tissue sample.

26. The method of claim 24 , wherein the preserved tissue sample is a paraformalin-fixed paraffin-embedded (FFPE) tissue sample.

27. The method of claim 1 , further comprising analyzing gene expression in the tissue sample.

28. The method of claim 1 , wherein the location of the binding agent is known prior to step (b).

29. The method of claim 1 , wherein the binding agent is immobilized directly or indirectly onto a bead of the plurality of beads.

30. The method of claim 1 , wherein the biological molecule of the biological sample is a protein.

Assignees

• Prognosys Biosciences Inc

Inventors

• Chee Mark S

Classifications

• B01L3/502715

  characterised by interfacing components, e.g. fluidic, electrical, optical or mechanical interfaces · CPC title

• C12Q1/6837 Primary

  using probe arrays or probe chips (C12Q1/6874 takes precedence) · CPC title

• C12Q1/6869

  Methods for sequencing · CPC title

• C12Q1/6841

  In situ hybridisation · CPC title

• C12Q1/6834

  Enzymatic or biochemical coupling of nucleic acids to a solid phase · CPC title